Imigran Dr

Sumatriptan succinate, the active ingredient in Imigran Dr, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as a tablet for oral use. It provides acute treatment of migraine attacks, with or without aura, in adult patients and is indicated for rapid relief of headache and associated symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Imigran Dr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution.

Imigran Dr (sumatriptan succinate) is a Triptan used in the acute management of migraine, a neurovascular headache disorder.

Migraine with aura: provides rapid relief of headache intensity and associated neurological symptoms. Migraine without aura: reduces pain and associated nausea, photophobia, and phonophobia. Acute migraine attack: aborts the attack when taken at onset, decreasing the need for additional medication.

Common and serious adverse reactions have been reported with sumatriptan use.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Flushing or warmth sensation - Nausea or mild stomach upset

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with other serotonergic agents

Before prescribing Imigran Dr, clinicians should consider several safety precautions.

Cardiovascular assessment: evaluate history of coronary artery disease, uncontrolled hypertension, or stroke. Contraindicated with ergot derivatives: avoid co‑administration due to additive vasoconstriction. Serotonergic drug caution: monitor patients taking SSRIs, SNRIs, or MAO inhibitors for serotonin syndrome. Dose limitation: do not exceed the recommended number of doses per month as advised by the prescriber. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Sumatriptan may interact with several medication classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors (e.g., phenelzine): risk of severe hypertension and serotonin syndrome. - Ergot alkaloids (e.g., ergotamine): additive vasoconstriction may cause coronary spasm. - Other triptans or ditans: increased risk of vasospastic events.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or TCAs: monitor for signs of serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels.